Tags

Type your tag names separated by a space and hit enter

Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012.
Neurologia. 2015 Sep; 30(7):416-24.N

Abstract

INTRODUCTION

Analysing drug consumption in large population groups lets us observe consumption trends and compare them between different settings.

OBJECTIVE

to analyse the time trends for consumption and costs of specific drugs used to treat dementia in the region of Madrid (Spain) and compare trends by sex and age cohort.

METHODS

Descriptive study of cholinesterase inhibitors (N06DA) and memantine (N06DX01) dispensed in Madrid between 2002 and 2012 and covered by the Spain's national health system. Consumption was calculated by analysing changes in DDD (defined daily doses) to find total and yearly increases. The cost was estimated based on DDD price. To compare consumption rates by age and sex, we calculated DDD per 100 inhabitants/day.

RESULTS

Between 2002 and 2012, consumption of drugs used to treat dementia increased sixfold. During this period, cholinesterase inhibitors accounted for 76.70% of the drugs consumed and memantine, 23.30%. The estimated cost rose by a by a factor of 5.7 over 11 years (or by a factor of 4 taking into account the use of generic drugs). In 2012, 2.42% of the patients aged 65 or over consumed cholinesterase inhibitors (women 2.82%, men 1.83%) and 0.90% consumed memantine (women 1.10%, men 0.61%). Consumption increased in age cohorts up to 86 to 90 (5.84% for cholinesterase inhibitors and 2.33% for memantine) and declined thereafter.

CONCLUSIONS

Consumption of cholinesterase inhibitors and memantine gradually increased, but consumption in 2012 did not reach levels equivalent to dementia prevalence figures. Pharmaceutical expenditure restraint measures may temporarily slow the cost increase temporarily but if the same trend of consumption persists, costs will rise.

Authors+Show Affiliations

Servicio Madrileño de Salud, Centro de Salud Pedro Laín Entralgo, Alcorcón, Madrid, España. Electronic address: mcanto.hoyos@salud.madrid.org.Servicio Madrileño de Salud, Centro de Salud Comillas, Área Centro, Madrid, España.Servicio Madrileño de Salud, Subdirección General de Compras de Farmacia y Productos Sanitarios, Consejería de Sanidad, Comunidad de Madrid, España.Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid, Madrid, España.Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid, Madrid, España.

Pub Type(s)

Journal Article

Language

eng spa

PubMed ID

24704249

Citation

de Hoyos-Alonso, M C., et al. "Consumption Trends for Specific Drugs Used to Treat Dementia in the Region of Madrid (Spain) From 2002 to 2012." Neurologia (Barcelona, Spain), vol. 30, no. 7, 2015, pp. 416-24.
de Hoyos-Alonso MC, Tapias-Merino E, Meseguer Barros CM, et al. Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012. Neurologia. 2015;30(7):416-24.
de Hoyos-Alonso, M. C., Tapias-Merino, E., Meseguer Barros, C. M., Sánchez-Martínez, M., & Otero, A. (2015). Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012. Neurologia (Barcelona, Spain), 30(7), 416-24. https://doi.org/10.1016/j.nrl.2014.02.007
de Hoyos-Alonso MC, et al. Consumption Trends for Specific Drugs Used to Treat Dementia in the Region of Madrid (Spain) From 2002 to 2012. Neurologia. 2015;30(7):416-24. PubMed PMID: 24704249.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012. AU - de Hoyos-Alonso,M C, AU - Tapias-Merino,E, AU - Meseguer Barros,C M, AU - Sánchez-Martínez,M, AU - Otero,A, Y1 - 2014/04/04/ PY - 2013/10/16/received PY - 2014/01/07/revised PY - 2014/02/02/accepted PY - 2014/4/8/entrez PY - 2014/4/8/pubmed PY - 2016/6/2/medline KW - Anticolinesterásicos KW - Cholinesterase inhibitors KW - Cost KW - Coste KW - Demencia KW - Dementia KW - Drug utilization KW - Farmacoepidemiología KW - Memantina KW - Memantine KW - Pharmacoepidemiology KW - Uso de fármacos SP - 416 EP - 24 JF - Neurologia (Barcelona, Spain) JO - Neurologia VL - 30 IS - 7 N2 - INTRODUCTION: Analysing drug consumption in large population groups lets us observe consumption trends and compare them between different settings. OBJECTIVE: to analyse the time trends for consumption and costs of specific drugs used to treat dementia in the region of Madrid (Spain) and compare trends by sex and age cohort. METHODS: Descriptive study of cholinesterase inhibitors (N06DA) and memantine (N06DX01) dispensed in Madrid between 2002 and 2012 and covered by the Spain's national health system. Consumption was calculated by analysing changes in DDD (defined daily doses) to find total and yearly increases. The cost was estimated based on DDD price. To compare consumption rates by age and sex, we calculated DDD per 100 inhabitants/day. RESULTS: Between 2002 and 2012, consumption of drugs used to treat dementia increased sixfold. During this period, cholinesterase inhibitors accounted for 76.70% of the drugs consumed and memantine, 23.30%. The estimated cost rose by a by a factor of 5.7 over 11 years (or by a factor of 4 taking into account the use of generic drugs). In 2012, 2.42% of the patients aged 65 or over consumed cholinesterase inhibitors (women 2.82%, men 1.83%) and 0.90% consumed memantine (women 1.10%, men 0.61%). Consumption increased in age cohorts up to 86 to 90 (5.84% for cholinesterase inhibitors and 2.33% for memantine) and declined thereafter. CONCLUSIONS: Consumption of cholinesterase inhibitors and memantine gradually increased, but consumption in 2012 did not reach levels equivalent to dementia prevalence figures. Pharmaceutical expenditure restraint measures may temporarily slow the cost increase temporarily but if the same trend of consumption persists, costs will rise. SN - 1578-1968 UR - https://www.unboundmedicine.com/medline/citation/24704249/Consumption_trends_for_specific_drugs_used_to_treat_dementia_in_the_region_of_Madrid__Spain__from_2002_to_2012_ L2 - http://www.elsevier.es/en/linksolver/ft/pii/S0213-4853(14)00034-6 DB - PRIME DP - Unbound Medicine ER -